NEW YORK (GenomeWeb News) — Molecular diagnostics developer Evogen said this week that it has licensed PCR probe technology from LGC.
Under the agreement, Evogen has signed a worldwide license for LGC's HyBeacons technology to augment its molecular diagnostics and detection technology, including the EvoCycler platform.
The exclusive license also gives Evogen the right to sub-license the technology within its market areas, the company said.
"The addition of LGC's HyBeacons technology to the EvoCycler platform substantially increases the performance of the assays that we will be providing to the clinical, environmental, and biodefense markets," Evogen CEO Sean Reineke said in a statement.
Evogen said it plans to offer a larger menu of molecular diagnostic tests for clinical, biodefense, and environmental applications using the HyBeacons technology.
"We anticipate that the HyBeacons assay menu will expand quickly in the near future through the joint efforts of Evogen, LGC, and our expanding network of partnerships," John McQuillian, LGC's director of Life and Food Sciences, said in the statement.
Financial terms of the agreement were not released.